ClinicalTrials.gg

Program

FXS0260

A development code.

Its studies are led by Fosun Pharma.

Furthest: phase 1, since Oct 25, 20261 company-led study, 1 open or runningNext primary completion: Dec 15, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma11 open or runningphase 1since Oct 25, 2026Oct 25, 2026Dec 15, 2028phase 1 · NCT07933666

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 25, 2026First study: phase 1 study in Solid Tumor Refractory to Conventional TreatmentFirst studyNCT07933666 · 20 planned · China

Ahead

  1. Dec 15, 2028Primary completion: phase 1 study in Solid Tumor Refractory to Conventional TreatmentNCT07933666

TargetBeta

PKMYT1 →read by rule
“FXS0260 is an orally administered, selective small-molecule inhibitor of PKMYT1”study text, by rule · the study

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07933666Solid Tumor Refractory to Conventional Treatment · China1Not yet recruitingDec 15, 202820

How it is read

Names in the registry

  • “FXS0260”, 1 entry

Codes read as this program: FXS0260.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.